These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2479329)

  • 1. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
    Rockwell S; Keyes SR; Sartorelli AC
    Anticancer Res; 1989; 9(4):817-20. PubMed ID: 2479329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies of porfiromycin as an adjunct to radiotherapy.
    Rockwell S; Keyes SR; Sartorelli AC
    Radiat Res; 1988 Oct; 116(1):100-13. PubMed ID: 3186923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1987 Nov; 47(21):5654-7. PubMed ID: 3664473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Jan; 45(1):213-6. PubMed ID: 2578093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM; Sartorelli AC
    Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
    Bizanek R; Chowdary D; Arai H; Kasai M; Hughes CS; Sartorelli AC; Rockwell S; Tomasz M
    Cancer Res; 1993 Nov; 53(21):5127-34. PubMed ID: 7693331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro.
    Rockwell S; Keyes SR; Sartorelli AC
    Cancer Res; 1988 Oct; 48(19):5471-4. PubMed ID: 2458178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.
    Rockwell S; Keyes SR; Loomis R; Kelley M; Vyas DM; Wong H; Doyle TW; Sartorelli AC
    Cancer Commun; 1991 Jun; 3(6):191-8. PubMed ID: 2049227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
    Pritsos CA; Keyes SR; Sartorelli AC
    Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porfiromycin as an adjunct to radiotherapy in young and old mice.
    Rockwell S; Hughes CS; Keyes SR; Sartorelli AC; Kennedy KA
    Exp Gerontol; 1993; 28(3):281-93. PubMed ID: 8344398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio.
    Rockwell S; Nierenburg M; Irvin CG
    Cancer Treat Rep; 1987 Oct; 71(10):927-34. PubMed ID: 3652056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
    Marshall RS; Rauth AM
    Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
    Keyes SR; Heimbrook DC; Fracasso PM; Rockwell S; Sligar SG; Sartorelli AC
    Adv Enzyme Regul; 1985; 23():291-307. PubMed ID: 3934922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
    Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
    Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
    Hughes CS; Irvin CG; Rockwell S
    Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.
    Pritsos CA; Sartorelli AC
    Cancer Res; 1986 Jul; 46(7):3528-32. PubMed ID: 3011250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.